Advertisement
Screener

Rein Therapeutics, Inc. (RNTX) Number of Reportable Segments

2.8 / 5 stars · 68/120 Roast Me

Rein Therapeutics, Inc. Number of Reportable Segments

Rein Therapeutics, Inc. (RNTX) reported Number of Reportable Segments of 1 Segment for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-26.

Financial Statements › Notes › Segment Reporting

us-gaap:NumberOfReportableSegments · last filed 2026-03-26

  • Rein Therapeutics, Inc. number of reportable segments for the quarter ending 2025-03-31 was 1.00 Segment.
  • Rein Therapeutics, Inc. number of reportable segments for fiscal 2025 was 1.00 Segment, a 0.00% change from fiscal 2024.
  • Rein Therapeutics, Inc. number of reportable segments for fiscal 2024 was 1.00 Segment.
Period endNumber of Reportable Segments 3 monthNumber of Reportable Segments 6 monthNumber of Reportable Segments 9 monthNumber of Reportable Segments 12 month
2025-12-311.00 Segment
10-K · filed 2026-03-26
2025-09-301.00 Segment
10-Q · filed 2025-11-14
2025-06-301.00 Segment
10-Q · filed 2025-08-14
2025-03-311.00 Segment
10-Q · filed 2025-05-15
2024-12-311.00 Segment
10-K · filed 2025-04-07

Similar stocks

Stock NameCountryMarket CapPE Ratio
HYPERION DEFI, INC. (HYPD)United States$0.065B
XBiotech Inc. (XBIT)United States$0.066B-1.56
Skye Bioscience, Inc. (SKYE)United States$0.061B-0.48
CalciMedica, Inc. (CALC)United States$0.061B-1.42
TALPHERA, INC. (TLPH)United States$0.060B
Boundless Bio, Inc. (BOLD)United States$0.059B-0.88
NOMAD POWER SOLUTIONS, INC. (NMAD)United States$0.058B
Connect Biopharma Holdings Ltd (CNTB)$0.069B-2.17
Yarrow Bioscience, Inc. (YARW)United States$0.070B
Annovis Bio, Inc. (ANVS)United States$0.056B-1.58